This post was originally published on this site One of the greatest privileges of my life was to care for my mother, who had Alzheimer’s disease. However, I was constantly fighting an internal battle. A feeling of inadequacy always bubbled beneath the surface. Many caregivers fight similar battles. This is why I wrote the following,…
This post was originally published on this site A Phase 1/2a trial testing the advanced solid tumor treatment candidate IMX-110 in Australia has been cleared by the U.S. Food and Drug Administration to enroll participants in the United States. Immix is now selecting the medical centers that will participate in the trial. Australia is the…
This post was originally published on this site Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will undergo a stem cell transplant, CASI Pharmaceuticals, its maker, announced. The product is also approved as a palliative treatment for patients who cannot take oral medicines.…
This post was originally published on this site The European Commission (EC) has expanded the use of Imbruvica (ibrutinib) to cover combinations with Gazyva (obinutuzumab) for previously untreated adults with chronic lymphocytic leukemia (CLL), and with MabThera (rituximab) for adults with Waldenström’s macroglobulinemia (WM). This decision follows a recent positive opinion from the European Medicines Agency’s…
This post was originally published on this site Cancer has a way of isolating us. Friends and family can be supportive, but sometimes they don’t understand what you’re going through. I have found that it helps to think of myself as one part of a larger community. In my 11-plus years as a follicular lymphoma…
This post was originally published on this site ADXS-NEO, an investigational cancer immunotherapy, induced an immune response against 90% of all cancer targets in a patient with metastatic microsatellite stable colorectal cancer (MSS-CRC), data from an ongoing Phase 1 trial show. ADXS-NEO, jointly developed by Advaxis and Amgen, is a new type of personalized cancer…
This post was originally published on this site Immunotep has completed patient enrollment for its Phase 2b trial evaluating eftilagimod alpha (IMP321) — an investigational therapy that stimulates the immune system to fight cancer — in combination with standard chemotherapy for women with hormone receptor (HR)-positive and HER2-negative advanced breast cancer. Combining active immunotherapy with…
This post was originally published on this site Alkahest’s experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer’s disease patients, results of a six-month Phase 2 clinical trial show. “These top-line results indicate a potential benefit of this plasma protein fraction in slowing the progression of cognitive decline in patients with…
This post was originally published on this site Progenics Pharmaceuticals has entered a collaboration with Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS) to support the development of new machine learning tools aimed at improving detection of prostate cancer through medical imaging. The project is the first collaborative effort in the U.S. to explore pioneering…
This post was originally published on this site Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label trial (NCT03907527), which is still recruiting patients, will be carried out in collaboration with the University of…
